All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-14T07:13:29.000Z

EHA 2019 | What impact does MRD status have on the outcomes of patients with AML undergoing allo-SCT?

Jun 14, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Richard Dillon from King's College, London, UK, talks to the AML Global Portal, about the impact of minimal residual disease (MRD) status on the outcomes of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT).

Dr. Dillon explains that patients who have a stem cell transplant for AML, and then relapse have very poor outcomes, with fewer than 20% of patients achieving long term survival. Dr. Dillon emphasizes that there is a lot of interest trying to identify patients who are at high risk of relapse after transplant so that physicians can intervene, to try and improve survival rates.

There have been a lot of studies over the years looking at MRD pre-transplant, and when this is measured using flow cytometry. The tests have found that patients who test positive have an extremely high relapse risk. Another method used to measure MRD that Dr. Dillon explains is using Polymerase chain reaction (PCR), which was used to test 107 patients in the UK, AML-17 trial. This trial looked at patients MRD status by PCR prior to transplant, this was important because the PCR test is more sensitive than flow MRD tests.

The results of the study found that are a group of patients who MRD+ that have levels below a defined threshold, therefore identifying patients who don't need any interventions. On the other hand, Dr. Dilon and his colleagues identified another group of patients who have high levels of MRD and patients with FLT3 mutations with any level of MRD, who have extremely poor outcomes after transplant, with only 17% of survival at 2 years after transplant.

Dr. Dilion and his team were able to define a population of patients that are at high risk of relapse, which can lead physicians to test for interventions that will ultimately reduce the risk of patients relapsing.

What impact does MRD status have on the outcomes of patients with AML undergoing allo-SCT?

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox